Baird Reiterates an 'Outperform' on Human Genome Sciences (HGSI); Benlysta Off to a Solid Start, Q311 Estimates Look Safe

Baird reiterates an 'Outperform' on Human Genome Sciences (NASDAQ: HGSI) price target of $32.

Baird analyst says, "Incrementally positive on HGSI following a solid Q211 report, showing Benylsta off to a strong US launch (revenue of $8M was in-line). While still early days, our checks - along with management commentary - suggest Benlysta is on a trajectory of rapidly accelerating uptake. Therefore, we remain confident in our above-consensus 2011 Benlysta estimates, and continue to want to hold HGSI shares for the next few quarterly prints. Remain aggressive buyers."

For more ratings news on Human Genome Sciences click here and for the rating history of Human Genome Sciences click here.

Shares of Human Genome Sciences closed at $23.22 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• McGraw Hill (MH) PT Raised to $15 at UBS
• UBS Reiterates Buy Rating on HF Sinclair (DINO)